Peroxisome Proliferator-Activated Receptors

New peroxisome proliferator-activated receptors study findings have been published by scientists at GlaxoSmithKline

Published in Obesity and Diabetes Week, June 7th, 2010

"In a recent clinical study, the thiazolidinedione (TZD) pioglitazone (Actos™) was reported to preserve cognitive function in patients with mild to moderate Alzheimer's disease and type II diabetes mellitus," scientists in Harlow, the United Kingdom report.

"TZDs are agonists of the nuclear hormone receptor peroxisome proliferator-activated receptor-gamma (PPAR gamma), are peripheral insulin sensitizers, and have recently been reported to increase mitochondrial biogenesis in the central nervous system and dendritic spine density. We report a transcriptional profile of the TZD pioglitazone and the non-TZD PPAR gamma agonist GW347845 in primary cortical culture. We...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2010-06-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry